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Glossary of Abbreviations 47 
BWF  = bronchial wash fluid 48 
EVLP  = ex vivo lung perfusion 49 
IL  = interleukin 50 
IL-1ra  = interleukin-1 receptor antagonist 51 
IR  = ischemia-reperfusion 52 
PGD  = primary graft dysfunction 53 
PaO2/FiO2 = partial pressure of arterial oxygen/fraction of inspired oxygen 54 
SD  = standard deviation 55 
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Central Message 70 
Adsorption of inflammatory mediators during ex vivo lung perfusion improves immediate 71 
post-transplant graft function by decreasing inflammatory response to reperfusion in pigs. 72 
 73 
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Perspective statement 76 
Current ex vivo lung perfusion protocols are limited by short perfusion times and scarce 77 
treatment options. Advancements in the perfusion protocols may improve the quality of 78 
donor lungs and result in increased rates of utilization. Implementation of an additional 79 
broad spectrum adsorber in perfusion circuits not only refines the current protocols, but 80 
also improves short-term graft function. 81 
 82 
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Abstract  93 
Objective: Improvement in ex vivo lung perfusion (EVLP) protocols could increase the 94 
number of donors available for transplantation and protect the lungs from primary graft 95 
dysfunction. We hypothesize that perfusate adsorption during EVLP reconditions the 96 
allograft to ischemia-reperfusion injury after lung transplantation. 97 
Methods: Donor pig lungs were preserved for 24h at 4°C, followed by 6h of EVLP 98 
according to the Toronto protocol. The perfusate was additionally adsorbed through a 99 
CytoSorb adsorber in the treatment group, whereas control lungs were perfused according 100 
to the standard protocol (n = 5, each). EVLP physiology and biochemistry were monitored. 101 
Upon completion of EVLP, a left single lung transplantation was performed. Oxygenation 102 
function and lung mechanics were assessed during a 4-hour reperfusion period. The 103 
inflammatory response was determined during EVLP and reperfusion. 104 
Results: The cytokine concentrations in the perfusate were markedly lower with the 105 
adsorber, resulting in improved EVLP physiology and biochemistry during the 6-hour 106 
perfusion period. Post-transplant dynamic lung compliance was markedly better during the 107 
4-hour reperfusion period in the treatment group. Isolated allograft oxygenation function 108 
and dynamic compliance were continued to be superior in the adsorber group at the end of 109 
reperfusion accompanied by a markedly decreased local inflammatory response.  110 
Conclusions: Implementation of an additional cytokine adsorber has refined the standard 111 
EVLP protocol. Furthermore, cytokine removal during EVLP improved immediate post-112 
transplant graft function together with a less intense inflammatory response to reperfusion 113 
in pigs. Further studies are warranted to understand the beneficial effects of perfusate 114 
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adsorption during EVLP in the clinical setting.      115 
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The implementation of ex vivo lung perfusion (EVLP) in donor lung management is the 138 
most significant advancement in lung transplantation over the last decade.1 Initially EVLP 139 
was introduced as a second-look procedure to high-risk donor lungs prior to 140 
transplantation. Growing experience with EVLP has assured its safety and efficacy in lung 141 
transplantation.2 Centers across the world have successfully adopted the procedure and 142 
reported increased utilization of donor lungs.3,4  143 
Other than donor lung assessment, EVLP also has a role in donor lung preservation. 144 
Accumulating evidence suggests that extension of donor ischemic time with an additional 145 
EVLP between the two cold static preservations does not have a negative impact on early 146 
outcomes of lung transplantation.5,6 Moreover, EVLP driven preservation of the standard 147 
criteria donor lungs have been shown to be effective and safe regardless of the perfusion 148 
protocols.7,8  149 
One of the limitations of the current EVLP protocols is the short perfusion times. To our 150 
knowledge, EVLP for more than 12h has not been reported so far using the three widely 151 
used EVLP protocols in the clinical setting. Several studies have been performed to 152 
optimize the EVLP protocols looking at the roles of atrial pressure,9 synchronous bronchial 153 
artery circulation,10 cellular and acellular perfusates,11 continued perfusate exchange,12 154 
negative pressure ventilation,13 perfusate oxygen concentration,14 continuous perfusate 155 
adsorption,15 and positioning of donor lungs.16 Combination of these strategies may result 156 
in prolonged EVLP times. 157 
EVLP simulates ischemia and reperfusion (IR) processes in lung transplantation, which is 158 
characterised by the release of inflammatory mediators into the perfusate.17 Kakishita et al 159 
have shown the feasibility of cytokine removal with an adsorbent membrane during 160 
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EVLP.18 Recently, we also demonstrated beneficial effects of perfusate adsorption during 161 
EVLP using a novel membrane (Cytosorb) in a prolonged cold ischemic injury model in 162 
pigs.15 In addition to marked cytokine removal, continuous perfusate adsorption improved 163 
the EVLP physiology and biochemistry in this setting.15 Moreover, increased expression 164 
of pro-inflammatory cytokines during EVLP has been shown to correlate with higher 165 
primary graft dysfunction (PGD) rates after lung transplantation.19 The present study is 166 
based on the hypothesis that perfusate adsorption during EVLP reconditions the allograft 167 
to IR induced injury after lung transplantation and improves short-term graft function. 168 
Improvement in EVLP could increase the number of donors available for transplantation 169 
and protect the lungs from PGD.  170 
 171 
METHODS 172 
All animals received humane care during experiments in accordance with the updated “The 173 
Guide for the Care and Use of Laboratory Animals” (8th Edition, US National Research 174 
Council). The animal use protocol was approved by the Veterinary Authorities of the Swiss 175 
Kanton of Zurich. Female domestic pigs were used.  176 
Pharmacokinetics of meropenem and methylprednisolone in EVLP perfusate from a 177 
previous trial 178 
The CytoSorb adsorber contains microporous beads, which are capable of adsorbing 179 
broad spectrum of mediators, including drugs.20 Thus, we first decided to analyse the 180 
perfusate samples collected at baseline, 1h, 3h, and in 3h intervals thereafter during our 181 
previous 12h EVLP trial.15 The two target drugs, Methylprednisolone (Medrol) and 182 
Meropenem (Meronem), were extracted from perfusate samples using a methanol 183 
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precipitation. For pharmacokinetics, samples were analyzed by liquid chromatography-184 
mass spectrometry using selected-reaction-monitoring assays. The system consists of a 185 
Thermo TSQ-Quantiva coupled to a Waters M-class UPLC. The LC was set up in reverse 186 
phase mode (C-18, 150µm x 5cm). External calibration curves, with a concentration range 187 
of 10-500 nM, were included. Quantification was performed using the Xcalibur Quan 188 
Browser software (Thermo Fisher Scientific, Waltham, MA). 189 
Lung retrieval, EVLP, and lung transplantation procedures 190 
The experimental procedures were previously described in detail elsewhere.21 The lungs 191 
were kept in a cold room for 24h at 4°C following pneumoplegia with Perfadex (XVIVO 192 
Perfusion, Göteborg, Sweden). EVLP was performed according to the Toronto protocol for 193 
6h.2 Perfusions were performed with or without the CytoSorb adsorber, commercially 194 
available for use in Europe with a CE mark, (CytoSorbents Inc, Monmouth Junction, NJ) 195 
according to an established methodology in a randomized fashion (n = 5, each).15 Recipient 196 
operation was started at 5h of EVLP. After a thoracotomy, the right pulmonary artery was 197 
encircled followed by a left pneumonectomy. Orthotopic left single lung transplantation 198 
was then performed and the recipients were observed for 4h. 199 
Physiological assessment during EVLP and after transplantation  200 
The allograft function was assessed hourly during EVLP and after reperfusion by means 201 
of pulmonary gas exchange, lung mechanics and vascular pressures. At the end of 4h of 202 
reperfusion, the allograft was challenged with a contralateral pulmonary artery occlusion 203 
for 5min, followed by clamping of the right main bronchus to a target pressure of 30 cmH2O 204 
for evaluation of the isolated allograft mechanics. 205 
Perfusate, plasma, bronchial wash fluid (BWF), and tissue collection and analyses 206 
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Perfusate and plasma samples were collected hourly. The Epoc blood analysis system 207 
(Epocal, Inc., Ottawa, ON, Canada) was used to measure perfusate and blood gases and for 208 
biochemistry.  209 
At the end of EVLP and transplantation, a bronchoalveolar wash was performed with 20 210 
mL of cold saline from the lower lobe segments of the right and left lungs, respectively. 211 
Approximately 15 mL were recovered during each wash. The recovered wash fluid was 212 
subjected to cytological assessment at the hospital’s core laboratories, using May–213 
Grünwald–Giemsa stained cytological specimens and subsequently processed as 214 
previously described for further analysis.22 Similarly, lung tissue samples were also 215 
collected at the end of each procedures.  216 
Assessment of the inflammatory response 217 
The inflammatory response was analysed in perfusate, plasma, and BWF samples using 218 
Milliplex MAP Porcine Cytokine/Chemokine Magnetic Bead Panel (EMD Millipore, 219 
Billerica, MA) by a luminex laboratory at the Mouse Metabolic Evaluation Facility of the 220 
University of Lausanne (Switzerland). Additionally, tissue expressions of interleukin (IL)- 221 
1β and IL-8 were analysed as previously described.23  222 
Protein assay  223 
The Pierce micro BCA kit was used to measure the total protein concentrations in perfusate, 224 
BWF, tissue, and plasma samples according to the manufacturer’s instructions (Thermo 225 
Scientific, Rockford, IL).  226 
Radiologic assessment of the lungs 227 
Lung X-rays taken at the end of EVLP were evaluated by a radiologist in a blinded fashion 228 
as previously described.15 229 
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Histological assessment of the lungs 230 
Tissue samples taken at the end of EVLP and transplantation were stained with 231 
hematoxylin and eosin and blindly assessed by two veterinary pathologists for any 232 
pathological changes. The most prominent features observed in the transplanted lungs were 233 
used to develop a scoring system. This was as follows: A) Evidence of neutrophil 234 
recruitment into the lungs, represented by the presence of neutrophils within vessels (1: 235 
moderate numbers, 2: high numbers, 3: vessels packed with neutrophils); B) Evidence of 236 
neutrophil emigration into the tissue (1: neutrophil rolling along vascular endothelial cells, 237 
2: neutrophils within vessel walls, 3: neutrophils immediately outside vessels); and C) 238 
Evidence of neutrophils within the tissue, represented by the presence of individual 239 
neutrophils within alveolar lumina (1: in rare alveoli, 2: in occasional alveoli, 3: in 240 
numerous alveoli). 241 
Statistical analyses 242 
All results are expressed as mean  standard deviation (SD). Mann–Whitney U-test was 243 
utilized, where data were non-continuous. Two-way analysis of variance for repeated 244 
measures was utilized, where such data contained a time component. Statistical analyses 245 
were performed with PRISM 5 software (GraphPad Software, Inc., La Jolla, CA). 246 
Differences were considered significant when the p-value is less than 0.05. 247 
 248 
RESULTS 249 
The effects of the adsorber on pharmacokinetics of meropenem and methylprednisolone 250 
under EVLP conditions   251 
Meropenem levels were diminished by more than 50% of the baseline at 1h and remained 252 
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stable throughout perfusions in the control group (Figure 1A). Interestingly, 253 
methylprednisolone levels were sustained at around 80% of the baseline during the 12h of 254 
EVLP period in the control group (Figure 1B). These results may indicate that tissue 255 
absorption of meropenem was much higher as compared to prednisolone during EVLP. 256 
However, the perfusate concentrations of meropenem and methylprednisolone were 257 
markedly decreased in the adsorber group compared with the control group (p<0.001, 258 
Figure 1A and 1B). The drug removal effect of the adsorber was more prominent for 259 
methylprednisolone than meropenem. 260 
Reproducibility of EVLP part 261 
Pre-retrieval characteristics of donor animals 262 
Donor body weight (control: 29.83.6 vs adsorber: 28.41.5 kg; p=0.67), donor static 263 
compliance (control: 23.62.5 vs adsorber: 25.33.5 mL/mbar; p=0.42) and cold ischemic 264 
time (control: 24.10.3 vs adsorber: 24.30.3 hours; p=0.42) did not differ significantly 265 
between the two groups. Of note, the last partial pressure of arterial oxygen/fraction of 266 
inspired oxygen (PaO2/FiO2) ratio was markedly higher in the control group compared with 267 
adsorber (65.93.5 vs 574.8 kPa; p=0.008). 268 
EVLP physiology and biochemistry  269 
During the 6h EVLP period, peak airway pressure was significantly lower in the adsorber 270 
group (p=0.045, Figure 2A). Dynamic compliance (p=0.27, Figure 2B) and pulmonary 271 
vascular resistance (p=0.26, Figure 2C) did not differ significantly between the two groups. 272 
Moreover, the pulmonary veno-arterial oxygen pressure gradient was markedly better in 273 
the adsorber group (p=0.016, Figure 2D).  274 
Electrolytes, such as hydrogen, potassium, and calcium continued to accumulate in the 275 
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perfusate during the 6-h EVLP period (Figure 2E-G). However, a trend towards a more 276 
physiologic pH (p=0.055, Figure 2E), and markedly decreased potassium (p=0.003, Figure 277 
2F) and calcium (p<0.001, Figure 2G) levels was observed in the adsorber group.  278 
Similarly, a gradual decrease in perfusate glucose concentrations combined with high 279 
lactate levels were the characteristics of pulmonary metabolism during EVLP (Figure 2H-280 
I). There was a trend towards lower glucose consumption rates (p=0.059, Figure 2H) and 281 
a significant decrease in lactate production in the adsorber group compared to the controls 282 
(p=0.004, Figure 2I).  283 
Inflammatory response 284 
Perfusate samples collected at 3h and 6h of EVLP were analyzed using a multiplex kit. 285 
Overall, the perfusate levels of IL-1α, IL-1β, IL-1 receptor antagonist (ra), IL-6, IL-8, IL-286 
10, IL-12, and IL-18 were found to gradually increased over time in the control group 287 
(Table 1). However, all analytes were significantly lower in the adsorber group during the 288 
6-hour EVLP period. Furthermore, the perfusate total protein concentration was also 289 
markedly lower in the adsorber group (80.26 vs 64.58.3 mg/mL; p=0.032). 290 
End-EVLP assessments 291 
The cytological examination found that macrophages were the predominant cell type in the 292 
BWF in both groups (Control: 85.99.3 vs Adsorber: 89.15.7 percent; p=0.68). The 293 
following parameters did not differ significantly, but they were lower the treatment group: 294 
Perfusate consumption (Control: 536163 vs Adsorber: 394119 mL; p=0.31) and 295 
radiologic lung injury scores (Control: 6.42 vs Adsorber: 4.41.5; p=0.205). In both 296 
groups, the histological changes were comparable and restricted to mild to moderate 297 
subpleural and interstitial edema and the presence of apoptotic leukocytes within vessel 298 
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lumina and, to a variable extent, within the occasionally observed mild bronchus associated 299 
lymphatic tissue (Supplement Figure A). 300 
Outcomes of lung transplantation 301 
Baseline characteristics of recipient animals 302 
Recipient body weight (control: 32.22.2 vs adsorber: 321.7 kg; p=1), recipient static 303 
compliance (control: 25.83.8 vs adsorber: 252.6 mL/mbar; p=0.92),  the PaO2/FiO2 ratio 304 
before thoracotomy (control: 64.66 vs adsorber: 61.56 kPa; p=0.69), and warm ischemic 305 
time (control: 71.48.7 vs adsorber: 764.2 minutes; p=0.45) did not differ significantly 306 
between the two groups.  307 
Post-transplant physiological parameters 308 
Recipient animals were supported hemodynamically using ringer's lactate solution 309 
throughout the procedure. Overall, mean arterial pressures were comparable between the 310 
two groups during the experimental procedures (p=0.135, Figure 3A).  311 
Dynamic pulmonary compliance was significantly higher throughout reperfusion in the 312 
adsorber group (p=0.031, Figure 3B). Although not reaching a statistical significance, 313 
systemic arterial (p=0.099, Figure 3C) and pulmonary venous (p=0.175, Figure 3D) 314 
oxygenation function were superior in the treatment group.  315 
After clamping the right pulmonary artery, allograft continued to provide a superior gas 316 
exchange function in the treatment group compared with control (3717 vs 61.811.8 kPa; 317 
p=0.056, Figure 3E). Similarly, isolated dynamic compliance was significantly better in 318 
the adsorber group (7.73.2 vs 12.92.2 mL/mbar; p=0.032, Figure 3D).  319 
Post-transplant inflammatory response 320 
The inflammatory response was assessed in plasma collected at baseline, 2h, and 4h of 321 
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reperfusion and BWF samples were collected at autopsy for 8 analytes. The plasma levels 322 
of IL-1ra, an acute phase protein, were significantly lower in the absorber group during the 323 
4-h reperfusion period (p=0.009, Figure 4). Other analytes in the plasma did not differ 324 
significantly between the two groups and the results are not presented. When we looked at 325 
the BWF samples, except for IL-1α, measurements of all other analytes were lower in the 326 
treated lungs (Table 2). For IL-1ra, IL-6, and IL-8, the difference was statistically 327 
significantly. In parallel with the BWF, tissue expressions of IL-1β (control: 4.40.8 vs 328 
adsorber: 3.50.6 ng/mL; p=0.056) and IL-8 (control: 213125 vs adsorber: 13776 329 
pg/mL; p=0.31) were lower in the treatment group (Figure 5, upper panel). On the other 330 
hand, total protein concentration of plasma (control: 54.96.6 vs adsorber: 52.93.4 331 
mg/mL; p=0.84), BWF samples (control: 62.952.4 vs adsorber: 33.842.4 mg/mL; 332 
p=0.22), and tissue (control: 3.20.1 vs adsorber: 30.3 mg/mL; p=0.31) were comparable 333 
between the two groups.  334 
Post-transplant assessments 335 
BWF cytology at autopsy showed predominantly neutrophilic response in both groups 336 
(Control: 59.323.9 vs Adsorber: 44.222.4 percent; p=0.42). The histological assessment 337 
of the lungs collected during the autopsy showed consistent changes in response to 338 
reperfusion, reflecting the recruitment of neutrophils into the lung. All animals exhibited 339 
moderate or high numbers of neutrophils in vascular lumina, in one animal in the control 340 
group several vessels were packed with neutrophils (Animal #5, Figure 5C). Vascular 341 
endothelial cells were generally found to be activated (Supplement Figure B); this 342 
coincided with evidence of neutrophil rolling along the endothelial cells, and in several 343 
animals also with proof of neutrophil emigration (Supplement Figure C), represented by 344 
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the presence of neutrophils in arterial walls and even in the perivascular tissue. Lastly, in 345 
most lungs’ neutrophils were found in alveoli (Supplement Figure D). The overall 346 
microscopic lung injury scoring was comparable between the two groups (5.22.7 vs 347 
4.21.6; p=1, Figure 5C). However, the presence of individual neutrophils within alveolar 348 
lumina (1.91 vs 11; p=0.29, Figure 5D) were lower, indicating a less intense 349 
inflammatory response in the adsorber group. Furthermore, the discordance between the 350 
two-pathologists related to the microscopical lung injury are given in detail in 351 
supplementary Table.   352 
 353 
DISCUSSION 354 
In the present study, we have further tested the beneficial effects of perfusate adsorption 355 
during EVLP on short-term post-transplant lung function in a pig EVLP lung transplant 356 
model. With this strategy, we have repeatedly shown that EVLP physiology and 357 
biochemistry were significantly improved.15 Furthermore, cytokine filtration during EVLP 358 
resulted in the preservation of post-transplant graft function, represented by enhanced gas 359 
exchange and lung mechanics, and a less intense inflammatory response to IR-injury in 360 
pigs (Figure 6). We conclude that implementation of an additional cytokine adsorber has 361 
refined the standard EVLP protocol and maybe beneficial to protect donor lungs from 362 
unwanted effects of PGD in lung transplantation. 363 
Other than cytokines, the adsorber removes a wide range of molecules such as damage- 364 
and pathogen-associated molecular patterns, metabolites, hormones, proteins, and drugs.20 365 
We have previously shown a certain albumin removal effect of the adsorber under EVLP 366 
conditions.15 Antibiotics, steroids, and heparin are generally added to the prime solution in 367 
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EVLP protocols. Thus, we first determined the pharmacokinetics of meropenem and 368 
methylprednisolone in perfusate samples collected during our previous trial. The impact of 369 
the adsorber on drug removal from perfusate was remarkable for both meropenem and 370 
methylprednisolone, but the latter more prominently in this study. Interestingly, tissue 371 
adsorption of meropenem as compared to methylprednisolone was much higher in the 372 
control lungs. To our knowledge, the impacts of the empiric use of antibiotics and steroids 373 
in EVLP has not been studied elsewhere, thus the clinical relevance of the reduced levels 374 
of these substances remains unclear. Therefore, we have decided not to change the current 375 
regime in the present study. However, dose adjustments are advised to reach therapeutic 376 
drug levels during treatment with CytoSorb in EVLP setting.  377 
Reproducibility in animal research and translation from bench to bedside are continuing to 378 
challenge the scientific community. Several guidelines have been published to improve 379 
reproducibility in research, yet the practice remains largely unchanged.24 We have 380 
previously shown the beneficial effects of continued perfusate adsorption with CytoSorb 381 
during a 12h EVLP period in pigs in a proof-of-concept study.15 In the present study, we 382 
have decided to perfuse the lungs for 6h only to mimic the clinical scenario. Furthermore, 383 
at this time point, significant cytokine clearance was achieved, accompanied by improved 384 
EVLP physiology during the initial trial.15 Overall, the previous outcomes of the EVLP 385 
part are reproduced in the present study. The treated lungs exhibited less intense pulmonary 386 
edema, determined by decreased airway pressures, during the EVLP period; lesser 387 
pulmonary compliance and radiologic lung injury scores provide further evidence of 388 
decreased lung edema. The short perfusion time may have prevented these outcomes 389 
reaching a statistical significance and subsequent histological evidence of quantitative 390 
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differences. Remarkably, oxygenation function of the treated lungs during EVLP was 391 
markedly better in the present study. Yet, gas exchange function during EVLP has been 392 
suggested as the least important parameter for assessing graft quality in acellular perfusion 393 
method.25 Other than physiological parameters, perfusate analyses provide insights 394 
regarding the quality of donor lungs. Glucose consumption and lactate production have 395 
been suggested as predictive markers for decision making during EVLP.26 In parallel with 396 
our previous findings, perfusate adsorption lead to markedly improved the pulmonary 397 
metabolism in this study. In combination with physiological and biochemical parameters, 398 
novel biomarkers are needed to accurately predict post-transplant outcomes of EVLP 399 
assessed donor lungs. 400 
Accumulating evidence suggests that EVLP simulates IR injury in lung transplantation. 401 
Restoration of pneumocyte function under normothermic conditions induces enhanced 402 
cytokine expression during EVLP,17 which is similar to the inflammatory response that is 403 
seen after reperfusion with the recipients’ blood in lung transplantation.27 Furthermore, an 404 
enhanced inflammatory response during EVLP has been shown to correlate with poor 405 
outcomes related to PGD.19 In line with our previous findings, the adsorber safely and 406 
effectively cleared the cytokines from the perfusate, resulting in improved EVLP 407 
physiology in this study. Kakishita et al also showed the feasibility of cytokine removal 408 
during EVLP, yet the EVLP physiology did not improve under the experimental conditions 409 
they used.18 The adsorber device used in their study is comprised of a cellulosic bead 410 
modified with a hexadecyl ligand. It is indicated for selective elimination of β2-411 
microglobulin from the circulating blood of patients with dialysis-related amyloidosis.28  412 
This differs from CytoSorb, where there are no ligands attached to the polymer, but which 413 
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functions on size selectivity and surface adsorption. Furthermore, the experimental 414 
conditions of the two studies were very different. The EVLP was initiated after a short 415 
warm-ischemic time, whereas the present study used a clinically relevant prolonged cold 416 
ischemic injury model.29 However, donor lungs undergo different types of insults, such as 417 
brain death, aspiration, pneumonia, and barotrauma in the clinical setting.30 The broad 418 
spectrum adsorber used in this study has a capability to adsorb not just cytokines, but also 419 
a wide range of other molecules.20 Thus, it is important to check the effects of perfusate 420 
adsorption in the clinical EVLP setting.  421 
Donor lung reconditioning via perfusate adsorption during EVLP has led to a superior post-422 
transplant lung function and decreased inflammatory response in this study. Donor driven 423 
alveolar macrophages have been thought to be the initiator of acute lung injury early after 424 
reperfusion. Cytokine release from alveolar macrophages further aggravates IR injury by 425 
the recruitment of recipient driven white blood cells into the allograft during the second 426 
phase of reperfusion.31 Expectedly, macrophages are the predominant cell type in BWF 427 
after EVLP, whereas a neutrophilic response became evident after reperfusion in this study. 428 
We further analyzed the local inflammatory response using a multiplex cytokine assay. For 429 
most analyzed cytokines/chemokines, levels were lower in the treated lungs, with IL-1ra, 430 
IL-6, and IL-8 being markedly reduced. The inhibition of an inflammatory response during 431 
EVLP and after reperfusion is probably the mechanism underlying the protection against 432 
IR related injury. Interestingly, other than IL-1ra, the systemic inflammatory response to 433 
reperfusion did not differ significantly in this study. Similarly, the histological examination 434 
showed that the type of inflammatory response (recruitment of neutrophils into the lungs) 435 
did not differ between treated and untreated lungs post transplantation, while the extent of 436 
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recruitment (with evidence of emigration and accumulation in alveolar lumina) was overall 437 
higher in untreated control lungs. IL-1α, IL-1β, IL-1ra, and IL-18 are belonging to the IL-438 
1 family cytokines that are being associated with acute and chronic inflammation.32 439 
Although the recombinant form of IL-1ra has been used as an anti-inflammatory drug in 440 
various inflammatory conditions, the soluble form is secreted by hepatocytes as an acute 441 
phase protein.33 We believe that elevated IL-1ra plasma levels are a surrogate marker of 442 
enhanced inflammation regulated by proinflammatory cytokines. Apparently, the main 443 
mechanism that underlies our results with Cytosorb is an increased protection against injury 444 
related to adsorption of inflammatory mediators. Nonetheless, we could not rule out that 445 
the mechanism behind this observed injury protection may be different, improving lung 446 
compliance or redirecting the perfusate flow to better oxygenated area.  447 
The main limitation of the present study is the lack of understanding the pathways involved 448 
in lung recovery during EVLP. Further studies are needed to understand the effects of the 449 
broad spectrum adsorber on the mechanisms underlying IR injury in lung transplantation. 450 
We have conducted the study with the least possible number of animals to reach a 451 
conclusion. The duration of reperfusion was only 4h, which is far shorter than the clinical 452 
definition of PGD. The non-selective nature of the adsorber should be carefully considered 453 
when planning treatments with anti-inflammatory molecules, such as IL-10. Taking into 454 
consideration of the limitations of the CytoSorb adsorber, modified EVLP protocol 455 
warrants further studies in the clinical setting. 456 
In summary, implementation of an additional cytokine adsorber has refined the standard 457 
EVLP protocol. Furthermore, cytokine removal during EVLP improved immediate post-458 
transplant graft function and was associated with a less intense inflammatory response to 459 
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reperfusion in pigs. Further studies are warranted to understand the beneficial effects of 460 
perfusate adsorption during EVLP in the clinical setting. 461 
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 580 
FIGURE LEGENDS 581 
CENTRAL PICTURE: 582 
Perfusate adsorption during ex vivo lung perfusion improves post-transplant lung function 583 
FIGURE 1: Pharmacokinetics of meropenem and methylprednisolone during the 12-584 
hour of ex vivo lung perfusion period. 585 
Perfusate concentrations of meropenem (A) and methylprednisolone (B) were measured at 586 
baseline, 1h, 3h, and in 3h intervals thereafter in samples collected during the initial trial.15 587 
The perfusate concentrations of meropenem and methylprednisolone were markedly 588 
decreased in the adsorber group compared with the control group (*** p < 0.001, between 589 
groups). The drug removal effect of the adsorber was more prominent for 590 
methylprednisolone than meropenem. Data are presented as percentage change from 591 
baseline and expressed as mean ± standard deviation. 592 
FIGURE 2: Ex vivo lung perfusion physiology and biochemistry.   593 
Pulmonary mechanics, vascular pressures, oxygenation function and perfusate gas analyses 594 
were recorded hourly during the 6-hour EVLP period. EVLP physiology, determined by 595 
peak airway pressure (A) and delta PO2 (D) was significantly better in the treatment group. 596 
EVLP biochemistry, determined by potassium (F), calcium (G), and lactate (I) levels was 597 
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also improved in the adsorber group. Pulmonary vascular resistance = Pulmonary artery 598 
pressure – (Left atrial pressure / Flow). Delta PO2 = left atrial pressure of oxygen – 599 
pulmonary arterial pressure of oxygen. Data are expressed as mean ± standard deviation (* 600 
p < 0.05, ** p < 0.01, *** p < 0.001, between groups).  601 
FIGURE 3: Post-transplant physiological outcomes. 602 
Mean arterial pressure (A), dynamic compliance (B), and systemic arterial PaO2/FiO2 ratio 603 
(C) were recorded at baseline, early after reperfusion and hourly thereafter. Dynamic 604 
pulmonary compliance was significantly higher throughout reperfusion in the adsorber 605 
group (B, * p < 0.05, between groups). Systemic arterial (C, p = 0.1) and pulmonary venous 606 
(D, p = 0.18) oxygenation function were also better in the treatment group. After occlusion 607 
of the contralateral anatomical structures, isolated allograft oxygenation function (E, p = 608 
0.056) and dynamic compliance (F, * p < 0.05, between groups) continued to be better in 609 
the treatment group. Matching results for each animal are presented. PaO2/FiO2, partial 610 
pressure of arterial oxygen/fraction of inspired oxygen; PA, pulmonary artery; MB, main 611 
bronchus; LTx, lung transplantation. Data are expressed as mean ± standard deviation.  612 
FIGURE 4: Plasma levels of soluble Interleukin 1 receptor antagonist were significantly 613 
lower in the treatment group after reperfusion. Data are expressed as mean ± standard 614 
deviation (** p < 0.01, between groups).  615 
FIGURE 5: Correlation between tissue cytokine expression and histological assessment 616 
of the allografts.   617 
Matching results for each animal are presented for tissue cytokines, IL-1β and IL-8 (upper 618 
panel) and microscopic lung injury, which was scored by two veterinary pathologists in a 619 
blinded fashion (lower panel). Tissue expressions of IL-1β (A, p = 0.056) and IL-8 (B, p = 620 
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0.31) were lower in the treatment group. The overall microscopic lung injury scoring was 621 
comparable between the two groups (C, p = 1). However, the presence of individual 622 
neutrophils within alveolar lumina (D, p = 0.29) were lower, indicating a less intense 623 
inflammatory response in the adsorber group. Data are expressed as mean mean ± standard 624 
deviation. Comparison was made by Mann–Whitney U-test. 625 
FIGURE 6: Ex vivo lung perfusion (EVLP) is characterised by the release of inflammatory 626 
mediators into the perfusate. In the present study, we have tested the beneficial effects of 627 
perfusate adsorption during EVLP on short-term post-transplant lung function in a pig 628 
EVLP lung transplant model. This strategy resulted in preservation of post-transplant graft 629 
function, by means of enhanced gas exchange and lung mechanics, via inhibition of 630 
inflammatory response to ischemia-reperfusion injury in pigs. 631 
Supplementary Figure: 632 
Histological features of lungs. A. Non-transplanted right lung after ex vivo lung perfusion 633 
(EVLP) with adsorber. Histological changes are restricted to the apoptosis of leukocytes 634 
within capillaries and in the peribronchiolar tissue (arrows). B-D. Transplanted left lung 635 
from the control group at autopsy. Overall histological score of 9. B. Most vessels (arrows) 636 
and capillaries (arrowheads) are packed with neutrophils. Score A3. C. Large vein with 637 
evidence of neutrophil emigration, represented by extensive rolling of neutrophils along 638 
endothelial cells (arrowheads) and the presence of neutropils within the perivascular tissue 639 
(arrows). Score B3. D. Individual to groups of neutrophils are present within alveoli 640 
(arrows). Score C3. Hematoxylin-eosin stain.  Bars = 10 µm. 641 
 642 
 643 
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TABLE 1: The expression of cytokines and chemokines in perfusate at 3-hour 644 
and 6-hour of ex vivo lung perfusion.   645 
Cytokine/Chemokine Levels in Perfusate 
Analytes 
Time 
points 
Control (pg/mL) Adsorber (pg/mL) P-value 
IL-1α 
3h 54 ± 49 6 ± 7 
* 0.029 
6h 67 ± 50 1 ± 2 
IL-1β 
3h 155 ± 60 51 ± 24 
** 0.006 
6h 613 ± 540 81 ± 45 
IL-1ra 
3h 294 ± 101 63 ± 32 
*** 0.001 
6h 1214 ± 535 35 ± 17 
IL-6 
3h 719 ± 340 602 ± 352 
** 0.006 
6h 2833 ± 821 791 ± 354 
IL-8 
3h 17121 ± 8944 943 ± 766 
** 0.006 
6h 28812 ± 11105 444 ± 343 
IL-10 
3h 72 ± 30 24 ± 18 
** 0.006 
6h 191 ± 107 4 ± 3 
IL-12 
3h 185 ± 63 74 ± 46 
** 0.006 
6h 404 ± 120 97 ± 51 
IL-18 
3h 8068 ± 4416 245 ± 94 
** 0.002 
6h 7980 ± 3647 131 ± 112 
 646 
IL, Interleukin; IL-1ra, IL-1 receptor antagonist. Data are expressed as mean ± 647 
standard deviation. Comparisons between the groups were made by two-way 648 
repeated measures analysis of variance.   649 
 650 
 651 
 652 
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TABLE 2: Inflammatory response in bronchial wash fluid samples at autopsy.   653 
Cytokine/Chemokine Levels in Bronchial Wash Fluid 
Analytes Control (pg/mL) Adsorber (pg/mL) P-value 
IL-1α 16 ± 11 16 ± 16 0.691 
IL-1β 358 ± 305 70 ± 157 0.056 
IL-1ra 2411 ± 2200 218 ± 133 ** 0.008 
IL-6 898 ± 207 286 ± 255 * 0.016 
IL-8 1415 ± 990 301 ± 259 * 0.032 
IL-10 16 ± 12 6 ± 7 0.151 
IL-12 125 ± 73 56 ± 81 0.095 
IL-18 122 ± 124 9 ± 13 0.067 
IL, Interleukin; IL-1ra, IL-1 receptor antagonist. Data are expressed as mean ± 654 
standard deviation. Comparisons between the groups were made by the Mann-655 
Whitney test.   656 
 657 
 658 
 659 
 660 
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Supplementary Table: The quantitative presentation of the discordance between the two-671 
pathologists related to the microscopical lung injury at the end of transplantation.   672 
 Score A Score B Score C Score Overall 
Controls 
1 1 1 [0.5-1] 1 3 
2 1.5 [1-1.5] 1 1 3.5 
3 2 2 3 7 
4 1 1 1.5 [1.5-2] 3.5 
5 3 3 3 9 
Adsorber 
1 2.5 [2-2.5] 1.5 0 4 
2 1 2 1 4 
3 2 2.5 2 6.5 
4 1 1.5 [1.5-2] 2 4.5 
5 1 1 0 2 
 673 
Tissue samples were stained with hematoxylin and eosin and blindly assessed by two veterinary 674 
pathologists for any pathological changes. The scoring system to assess lung injury: A) Evidence 675 
of neutrophil recruitment into the lungs (1: moderate, 2: high, 3: vessels packed with neutrophils); 676 
B) Evidence of neutrophil emigration into the tissue (1: neutrophil rolling along vascular 677 
endothelial cells, 2: neutrophils within vessel walls, 3: neutrophils immediately outside vessels); 678 
and C) Evidence of neutrophils within the tissue, represented by the presence of individual 679 
neutrophils within alveolar lumina (1: in rare alveoli, 2: in occasional alveoli, 3: in numerous 680 
alveoli). The results showed a concordance in most of the cases with a very small disagreement in 681 
5 tissues. Those cases showing disagreement were re-evaluated with particular emphasis on the 682 
inclusion of all areas of the sections, and a final definitive score was reached. The discordant 683 
results are given in red. 684 
 685 
